Sotalol (hydrochloride)

Reference compound

Adrenergic Receptor; Potassium Channel

4°C (Powder, sealed storage, away from moisture)

Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3].

DMSO: 100 mg/mL (ultrasonic)|H2O: ≥ 100 mg/mL

Sotalol hydrochloride (MJ 1999) is a non-selective competitive beta-adrenergic receptor antagonist that also exhibits Class III antiarrhythmic properties by its inhibition of potassium channels^[1][2].
IC50 & Target: beta-adrenergic receptor^[1]; Potassium channels^[1]
In Vitro: Sotalol hydrochloride (MJ 1999) is an adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. Sotalol hydrochloride is a competitive beta adrenoceptor antagonist devoid of membrane-stabilizing activity and intrinsic sympathomimetic activity that has no preferential actions on beta 1 or beta 2 responses. Sotalol hydrochloride causes concentration-dependent increases in the contractility of isolated ventricular tissue that is not blocked by previous beta or alpha blockade or catecholamine depletion. Sotalol hydrochloride consistently reduces the heart rate to a greater degree than propranolol and causes significantly less cardiac suppression than propranolol at a given heart rate^[1].

Sotalol hydrochloride is not only a beta blocker but a class III antiarrhythmic drug. Its possible antifibrillatory activity was therefore investigated in both the ventricles and atria of dog heart in situ, since vulnerability to fibrillation is not the same in both these parts of the myocardium^[2].